Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1467)	11/26/2003 10:07:58 AM
From: Biomaven	Respond to of 1826

The latest Journal of Clinical Oncology has an editorial about apripent (Emend, the MRK Substance P antagonist) approved earlier this year. But the editorial contains some favorable Aloxi references (bolding added by me): To further complicate the recommendations for the management of these patients, in July 2003 palonosetron (Aloxi; MGI Pharma Inc, Bloomington, MN) was approved by the US Food and Drug Administration for the prevention of acute and delayed emesis following moderately emetogenic chemotherapy. 29 That approval and the clinical investigations behind it make palonosetron a standard of care for those receiving moderately emetogenic chemotherapy. The available data support the use of the combination of aprepitant, palonosetron, and dexamethasone in patients receiving moderately emetogenic chemotherapy. However, in the era of evidence-based medicine, a clinical trial of this three-drug regimen will be required before modification of guidelines to permit the routine addition of aprepitant for the prevention of emesis following regimens containing doxorubicin, cyclophosphamide, and carboplatin. Kris: J Clin Oncol, Volume 21(22). November 15,2003. 4077-4080 Peter

To: Icebrg who wrote (1467)	2/6/2004 4:28:32 PM
From: Icebrg	Read Replies (2) \| Respond to of 1826

MGI Pharma downgraded to "neutral" Friday, February 06, 2004 12:49:59 PM ET Banc of America NEW YORK, February 6 (New Ratings) - Analysts at Banc of America Securities downgrade MGI Pharma Inc (MOGN) from "buy" to "neutral." The target price is set to $48. Shares of MGI Pharma, an oncology-focused biopharmaceutical company, are currently trading at $48.62. According to Banc of America Securities' research note published this morning, the downgrade in rating is based on valuation. The company's share price has appreciated significantly since July 2003, the analysts mention. MGI Pharma's shares are currently trading at a price above the target price, the analysts say. The company is scheduled to report healthy results and encouraging guidance on February 11, which is already factored into its share price, the analysts add. According to Banc of America Securities, the demand for MGI Pharma's drug, Aloxi, is expected to robust in 2004. The analysts believe that the company's performance is likely to be driven by Aloxi in the near future, and 2004 estimates for Aloxi have been raised from $75 million to $85 million. The company's revenues and profits are expected to be boosted by the expansion of the Aloxi agreement with Helsinn for a PONV indication and oral CINV formulation, the analysts mention. The EPS estimate for 2003 is -$2.12. The EPS estimate for 2004 has been raised from -$0.21 to -$0.01. Banc of America Securities downgrades MGI Pharma Inc from "buy" to "neutral” newratings.com